Posts

Missed Us at Oslo Innovation Week?

Luckily, all our events at Oslo Innovation Week and Forskningsdagene are available for a rerun. Have a look!

We had great audiences during our three events on the 27th and 28th of September. If your were not among them, sitting in the brand new science centre of the Norwegian Cancer Society, do not despair. The events were all live streamed on Facebook. You still have a chance to experience them right here.

The events were co-hosted with our partners the Norwegian Cancer Society, the Norwegian Radium Hospital Research Foundation (Radforsk), IBM, Cancer Research UK, Norway Health Tech and EAT.

 

The first event of the week was titled “Antibiotic resistance and cancer – current status, and how to prevent a potential apocalyptic scenario”.

Antibiotic resistance and cancer – Current status, and how to prevent a potential apocalyptic scenario #OIW2017

Posted by Kreftforeningen on Tuesday, September 26, 2017

 

Our secondary event had the title “Cancer research and innovation – benefit for patients”.

Cancer research and innovation – benefit for patients #OIW2017

Posted by Kreftforeningen on Wednesday, September 27, 2017

 

The third and final event on our Oslo Innovation Week calendar was about how big data may transform the development of cancer treatments. 

How Big Data may transform the development of cancer treatments #OIW2017

Posted by Kreftforeningen on Wednesday, September 27, 2017

Presentations from Cancer Crosslinks 2014

Cancer Crosslinks 2014, January 23, was the 6th edition of this annual oncology conference bringing together hematologists, oncologists and the industry in Norway.

This years conference was developed and hosted in collaboration with partners BMS, Amgen and the Institute for Cancer Research, Oslo University Hospital. The feedback from the more than 220 participants was as always very positive, and we promise to come back with a even more exciting 7th edition of Cancer Crosslinks in January 2015.

Below you may find the main presentations featured at Cancer Crosslinks 2014, including the international keynote presentations from Professor Mario Sznol, Yale Cancer Centre and Professor Cornelis van de Velde, ECCO President. Here you may watch these presentations recorded at the Cancer Crosslinks conference.


Opening Keynotes:

“Opportunities, challenges and visions for cancer research and treatment”

Prof. Kjell Magne Tveit, Head of Department of Oncology, Oslo University Hospital

“Current trends in oncology drug development”
Prof. Gunnar Sæter, Head of the Institute for Cancer Research, Oslo University Hospital

Main session: New treatment modalities – need for a multidisciplinary approach

International Keynote:
“Cancer immunotherapies – novel treatment opportunities and their implications”
Prof. Mario Sznol, Yale Cancer Center, New Haven, CT, USA

International Keynote:

“Multidisciplinary collaboration for patient-centric oncology”
Prof. Cornelis van de Velde, Leiden University Medical Centre, Netherlands, ECCO President

“Optimizing treatment for each patient: MetAction as a Norwegian initiative”
Kjetil Boye MD, PhD; Oslo University Hospital as representative for the MetAction team
Find more info on Cancer Crosslinks 2014 here.

Two Oslo Cancer Cluster Board members receive K.G. Jebsen funding

Despite keen competition from other outstanding medical research groups, Oslo Cancer Cluster Board members Professor Ragnhild A. Lothe and Professor Rolf Bjerkvig have won the competition for funds for new K.G. Jebsen centres in the field of medicine – a long side John-Bjarne Hansen. 


By giving NOK 16 million to each of the three new centres, the Kristian Gerhard Jebsen Foundation wants to give a real boost to research and, not least, to contribute to excellent medical research benefiting patients sooner. In addition to the grants from the Foundation, each centre will also be allocated a substantial sum by its own institutions.

Focus on cancer research
It is worth noting that two of the new centres this year are cancer research centres. The centre at the University of Bergen led by Rolf Bjerkvig works on cancer of the brain, with particular focus on translating research results from laboratories into patient treatment. The centre is a collaboration between several research groups and hospital departments, and it is part of an international research network based in Luxembourg.

Ragnhild Lothe’s centre at Oslo University Hospital aims to develop better diagnostic and treatment methods for rectal cancer, and to help to improve hospital efficiency and benefit patients. Lothe believes that the establishment of a dedicated centre could encourage more young doctors and researchers to take an interest in this serious form of cancer, which is actually the second most common form of cancer in Europe and is currently only survived by around half the patients.

Of the 14 K.G. Jebsen Centres for Medical Research that will have been established in 2014, five work on cancer-related research. In a competition in which the primary criterion is quality, this is an indication that Norwegian cancer research is already at the forefront of the field, also in the international context

The new centre for medical research that is led by John-Bjarne Hansen will work on venous thromboembolism (VTE), which is a generic term for cardiovascular problems that affect almost 10,000 Norwegians every year.

Two of five focused research areas at Oslo University Hospital to cancer
As well as the K.G. Jebsen Centre – Professor Ragnhild Lothe also received one of five “Focused Research Areas at Oslo University Hospital 2014 – 2018”  for the colorectal SMART project.

Her research colleague Arne Kolstad, also received this appointment for his project within Cancer Immunotherapy, where both the Section for Cell Therapy and The Section for Immunology are major partners.

This clearly shows the strength of the cancer research performed at the Oslo University Hospital, when two of five focused research areas that will run in the next four years, goes to cancer.

Read more on this here (only in Norwegian).


Read more:

Ragnhild Lothes group.

Rolf Bjerkvigs group.

Arne Kolstads group.

Facts about the Kristian Gerhard Jebsen Foundation:
The Foundation was established in order to honor the memory of shipping magnate Kristian Gerhard Jebsen and his contribution to Norwegian and international shipping and business. The Foundation was established by Jebsen’s wife Aud Jebsen and the family in 2009.  At the turn of the year 2012/2013, the Foundation’s equity was NOK 916.6 million. Since the Foundation was established, it has awarded a total of NOK 324 million, NOK 274 million of which to Norwegian research. Further information about the foundation is available at the web site: www.stiftkgj.no

 

Norwegian Cancer Society grant MNOK 160

The 2013 year’s grant to cancer research in Norway, 160 million NOK (EUR 20 M) is the largest grant the Norwegian Cancer Society has ever given.

“It is fantastic that we are able to provide such a large amount to our top cancer researchers in Norway”, says Secretary-General Anne Lise Ryel, Norwegian Cancer Society. “This is made possible thanks to our big and small, but always generous donors and members”.

The money will be divided among 121 projects at 12 research institutions across the country. The three institutions that will receive the most are: Oslo University Hospital (MNOK 73), the University of Oslo (MNOK 35) and the University of Bergen (MNOK 24). Download a full overview over the projects here (in Norwegian).

Enables quality boost
For Oslo Cancer Cluster member NTNU, the Norwegian University of Science and Technology, the grants constitute a significant contribution to the university’s cancer research: “The money enables us to boost the quality of our research”, says Dean Stig Slørdahl from the Faculty of Medicine. “It was a great joy to receive this funding, especially when we know that only the best projects receives funding.”

One of the cancer researchers at NTNU that got funding for here project is Bodil Merete Kavli, whom you can read more about in the Cancer Society’s blog. She’s trying to find out which mechanisms inside the cells causes the development of lymphoma cancer. Thanks to the award from the Cancer Society, Kavli is now able to finance a four year research position.

About The Norwegian Cancer Society
The society is the largest non-government sponsor of independent cancer research in Norway. Over the last 10 years the Norwegian Cancer society  has granted 1.6 billion NOK (EUR 2bn) to cancer research. This represents over 25 prosent of total resources Norwegian researchers have at their disposal for their research. Read more here: www.kreftforeningen.no

Pucture: Cancer researcher Bodil Merete Kavli at NTNU, surprised by the Cancer Society and Norwegian Television. Photo: Arild Domaas, NCS

Portfolio Items